GET THE APP

..

Journal of Nephrology & Therapeutics

ISSN: 2161-0959

Open Access

Emmanuel Anteyi

Clinical Research & Development, Kibow Biotech, Inc 4781 West Chester Pike, Newtown Square, PA 19073, USA

Publications
  • Mini Review   
    Differentiating Sodium-Glucose Cotransporter 2 Inhibitors from Live Biotherapeutic Products (Probiotics) as Novel Therapeutic Intervention to Slow CKD Progression
    Author(s): Emmanuel Anteyi* and Natarajan Ranganathan

    Chronic kidney disease (CKD) is a global public health problem with high morbidity and mortality, from cardiovascular complications. CKD is a progressive and irreversible deterioration of kidney function with complex pathophysiological and pathogenetic pathways due to diverse etiologies and risk factors. Progression of CKD has a common complex and interrelated immunological and metabolic pathway resulting in inflammation and oxidative stress processes. This progression manifests clinically as irreversible functional and structural damage. The primary aim of therapeutic intervention in CKD management is delay progressive loss of function, and to prevent and manage complications. Recent approaches to slowing CKD progression include therapy with sodium-glucose cotransporter 2 inhibitor (SGLT2) and gut microbiome modulation with probiotics, based on beneficial clinical outcomes of metabol.. Read More»
    DOI: 10.37421/2161-0959.2022.12.415

    Abstract HTML PDF

Google Scholar citation report
Citations: 784

Journal of Nephrology & Therapeutics received 784 citations as per Google Scholar report

Journal of Nephrology & Therapeutics peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward